Ken Griffin Sangamo Therapeutics, Inc Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Sangamo Therapeutics, Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 50,400 shares of SGMO stock, worth $132,552. This represents 0.0% of its overall portfolio holdings.

Number of Shares

50,400

Previous 15,300 229.41%

Holding current value

$132,552

Previous $5,000 760.0%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$0.32 - $1.1 $78,758 - $270,733	246,121 Added 51.18%	727,057 $625,000
Q2 2024 Aug 14, 2024	BUY	$0.36 - $0.65 $154,455 - $278,878	429,044 Added 826.8%	480,936 $173,000
Q1 2024 May 15, 2024	SELL	$0.42 - $1.38 $495,349 - $1.63 Million	-1,179,404 Reduced 95.79%	51,892 $34,000
Q4 2023 Feb 14, 2024	SELL	$0.3 - $0.63 $990,485 - $2.08 Million	-3,301,619 Reduced 72.84%	1,231,296 $664,000
Q3 2023 Nov 14, 2023	BUY	$0.58 - $1.47 $21,983 - $55,715	37,902 Added 0.84%	4,532,915 $2.72 Million
Q2 2023 Aug 14, 2023	BUY	$1.11 - $1.74 $1.4 Million - $2.2 Million	1,261,863 Added 39.03%	4,495,013 $5.84 Million
Q1 2023 May 15, 2023	BUY	$1.66 - $3.67 $3.03 Million - $6.71 Million	1,828,004 Added 130.09%	3,233,150 $5.69 Million
Q4 2022 Feb 14, 2023	BUY	$2.77 - $5.07 $2.7 Million - $4.95 Million	976,491 Added 227.8%	1,405,146 $4.41 Million
Q3 2022 Nov 14, 2022	SELL	$4.27 - $6.39 $836,270 - $1.25 Million	-195,848 Reduced 31.36%	428,655 $2.1 Million
Q2 2022 Aug 15, 2022	BUY	$3.28 - $6.21 $368,327 - $697,351	112,295 Added 21.92%	624,503 $2.59 Million
Q1 2022 May 16, 2022	SELL	$5.23 - $7.82 $780,357 - $1.17 Million	-149,208 Reduced 22.56%	512,208 $2.98 Million
Q4 2021 Feb 14, 2022	BUY	$7.29 - $10.97 $1.95 Million - $2.93 Million	267,306 Added 67.83%	661,416 $4.96 Million
Q3 2021 Nov 15, 2021	SELL	$9.01 - $12.01 $3.56 Million - $4.74 Million	-395,059 Reduced 50.06%	394,110 $3.55 Million
Q2 2021 Aug 16, 2021	SELL	$10.17 - $12.64 $4.73 Million - $5.88 Million	-465,554 Reduced 37.1%	789,169 $9.45 Million
Q1 2021 May 17, 2021	BUY	$10.88 - $17.05 $7.11 Million - $11.1 Million	653,646 Added 108.75%	1,254,723 $15.7 Million
Q4 2020 Feb 16, 2021	SELL	$9.23 - $18.18 $6.83 Million - $13.5 Million	-740,273 Reduced 55.19%	601,077 $9.38 Million
Q3 2020 Nov 16, 2020	BUY	$9.38 - $12.48 $9.31 Million - $12.4 Million	992,494 Added 284.5%	1,341,350 $12.7 Million
Q2 2020 Aug 14, 2020	SELL	$6.21 - $11.83 $7.09 Million - $13.5 Million	-1,141,963 Reduced 76.6%	348,856 $3.13 Million
Q1 2020 May 15, 2020	BUY	$5.05 - $8.85 $2.65 Million - $4.65 Million	525,400 Added 54.42%	1,490,819 $9.5 Million
Q4 2019 Feb 14, 2020	SELL	$8.03 - $11.7 $9.83 Million - $14.3 Million	-1,224,096 Reduced 55.91%	965,419 $8.08 Million
Q3 2019 Nov 14, 2019	BUY	$9.05 - $12.22 $2.56 Million - $3.45 Million	282,533 Added 14.82%	2,189,515 $19.8 Million
Q2 2019 Aug 14, 2019	BUY	$8.75 - $13.03 $14.4 Million - $21.5 Million	1,650,290 Added 642.91%	1,906,982 $20.5 Million
Q1 2019 May 15, 2019	BUY	$7.72 - $12.81 $565,528 - $938,396	73,255 Added 39.93%	256,692 $0
Q4 2018 Feb 14, 2019	SELL	$9.51 - $16.6 $3.14 Million - $5.48 Million	-329,924 Reduced 64.27%	183,437 $2.11 Million
Q3 2018 Nov 13, 2018	BUY	$13.05 - $19.05 $3.89 Million - $5.67 Million	297,808 Added 138.16%	513,361 $0
Q2 2018 Aug 10, 2018	SELL	$13.9 - $19.8 $22,754 - $32,412	-1,637 Reduced 0.75%	215,553 $0
Q1 2018 May 11, 2018	SELL	$16.7 - $26.35 $1.74 Million - $2.75 Million	-104,458 Reduced 32.48%	217,190 $4.13 Million
Q4 2017 Feb 09, 2018	SELL	$11.6 - $17.35 $495,865 - $741,660	-42,747 Reduced 11.73%	321,648 $5.28 Million
Q3 2017 Nov 09, 2017	BUY	$8.4 - $15.0 $3.06 Million - $5.47 Million	364,395	364,395 $5.47 Million

Others Institutions Holding SGMO

# of Institutions

115

Shares Held

56.4M

Call Options Held

576K

Put Options Held

1.17M

View Full List

About SANGAMO THERAPEUTICS, INC

Ticker SGMO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 156,552,992
Market Cap $412M
Description
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucle...

More about SGMO

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account